“…In an editorial, Clavel, Iung and Pibarot4 compare these epidemiological findings to other studies pointing out that incidence rates in some studies were based on echocardiographic screening, which identifies subclinical disease, whereas the current study included only patients with a hospitalisation for valvular heart disease. They also note the sex differences in types of valve disease.…”
“…In an editorial, Clavel, Iung and Pibarot4 compare these epidemiological findings to other studies pointing out that incidence rates in some studies were based on echocardiographic screening, which identifies subclinical disease, whereas the current study included only patients with a hospitalisation for valvular heart disease. They also note the sex differences in types of valve disease.…”
“…With the ageing of the western populations, the burden of aortic stenosis is expected to increase [4][5][6][7][8][9]. The majority of aortic stenosis is degenerative and shares risk factors with those of atherosclerosis [7,[10][11][12][13][14][15], e.g. hypertension, advanced age, smoking, metabolic syndrome, hyperlipidemia, obesity, diabetes and being male.…”
This study aims at determining the temporal trends and the socioeconomic differences in treatment and mortality following a diagnosis of aortic stenosis. Methods and results: A total of 45,026 patients with a first-time diagnosis of aortic stenosis were identified in the Danish National Patient Registry in the period 2000-17. The risk of AVR within the first year after diagnosis decreased (OR = 1.84 in 2000-02 compared to 2015-16) and the risk was lower in the low-level educational group (OR = 0.85) and in the medium-level group (OR = 0.94) compared to high-level education. The risk of death after AVR within the first year decreased (OR = 2.25 in 2000-02 compared to 2015-16) and the risk was higher in the low-level educational group (OR = 1.32) and in the medium-level group (OR = 1.28) compared to highlevel education. The risk of death within the first year after diagnosis, for those patients who did not get an AVR during the follow-up, decreased (OR = 3.08 in 2000-02 compared to 2015-16) and the risk was higher in the low-level educational group (OR = 1.21) and in the medium-level group (OR = 1.10) compared to high-level education. Conclusion: Since 2000 there has been a decrease in both AVR treatment rate, mortality rate after AVR and mortality rate in patients not receiving AVR. For patients with lower-level education there is lower AVR treatment rate, higher mortality rate after AVR and higher mortality rate in patients not receiving AVR.
“… 4 , 5 , 6 Figure 1 Incidence of valvular heart diseases (VHDs) according to the sex of the patient. 5 (A) Incidence per 100,000 person-years of VHDs and ( B ) relative frequencies in % of VHDs in Sweden, according to the sex of the patients. The pink bars represent the data for women and the blue bars represent the data for men.…”
mentioning
confidence: 99%
“…AR, aortic regurgitation; AS, aortic stenosis; MR, mitral regurgitation; MS, mitral stenosis; PR, pulmonary regurgitation; PS, pulmonary stenosis; TR, tricuspid regurgitation; TS, tricuspid stenosis. From Clavel et al 5 (The data presented in this figure are obtained from the study of Andell et al 4 ) with permission from BMJ Publishing Group Ltd. …”
mentioning
confidence: 99%
“… Incidence of valvular heart diseases (VHDs) according to the sex of the patient. 5 (A) Incidence per 100,000 person-years of VHDs and ( B ) relative frequencies in % of VHDs in Sweden, according to the sex of the patients. The pink bars represent the data for women and the blue bars represent the data for men.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
